RUNX1 and colorectal carcinoma: The clinical relevance of this pathway was underscored by both in vitro and in vivo validations, revealing that RUNX1 directly regulates MUC13, highlighting a potent target for potential therapeutic interventions intended for mitigating metastasis in CRC.